VISION子研究:68Ga-PSMA-11 PET/CT判读确定177Lu-PSMA-617放射性配体治疗患者资格的判断者间一致性
该VISION子研究从VISION研究中随机选取125例68Ga-PSMA-11 PET/CT扫描(75例纳入和50例排除),由3名独立中心判读者回顾性评估,评估VISION判读标准下的判断者间变异性和判断者内重复性。判断者间平均一致率为0.85(Fleiss κ=0.60,95%CI 0.50-0.70),判断者内一致率为0.90-0.95(Cohen κ=0.76-0.89),表明VISION判读规则易于学习且具有良好的重复性。
要点
- 判断者间平均一致率0.85,Fleiss κ=0.60(95%CI 0.50-0.70),为中等至高度一致。
- 判断者内一致率0.90-0.95,Cohen κ=0.76-0.89,为高度至几乎完美重复性。
- 3名判读者对75例VISION纳入病例中的66例全部达成一致。
核心结论
- 使用VISION判读标准评估68Ga-PSMA-11 PET/CT扫描观察到中等至高度的判断者间一致性和高度至几乎完美的判断者内重复性。
- VISION中应用的判读规则易于学习并表现出良好的重复性。
研究设计与样本
- VISION子研究从VISION研究中随机选取125例68Ga-PSMA-11 PET/CT扫描(75例纳入和50例排除),由3名独立中心判读者回顾性评估。
- 随机抽取20例(12例纳入和8例排除)重新判读以评估判断者内重复性,分类基于VISION判读标准。
主要发现
- 判断者间变异:判读者对77%的病例达成一致(总体平均一致率0.85;Fleiss κ=0.60,95%CI 0.50-0.70)。
- 两两一致率分别为0.82、0.88和0.84,对应Cohen κ分别为0.54(95%CI 0.38-0.71)、0.67(95%CI 0.52-0.83)和0.59(95%CI 0.43-0.75)。
- 判断者内重复性:一致率分别为0.90、0.90和0.95,对应Cohen κ分别为0.78(95%CI 0.49-0.99)、0.76(95%CI 0.46-0.99)和0.89(95%CI 0.67-0.99)。
- 本子研究中判为纳入的总病例中实际VISION纳入病例数:判读者1为93例中71例(一致率0.76,95%CI 0.66-0.85),判读者2为88例中70例(0.80,95%CI 0.70-0.87),判读者3为96例中73例(0.76,95%CI 0.66-0.84)。
- 所有判读者对75例VISION纳入病例中的66例达成一致。
关键数值与推荐
- VISION判读标准:至少1个PSMA阳性病灶且无满足排除标准的PSMA阴性病灶的扫描判为纳入病例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[ 68Ga]Ga-PSMA-11 ( 68Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)-positive tumors on PET scans. In the VISION study, 68Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [177Lu]Lu-PSMA-617 (177Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of 68Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, 68Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50-0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38-0.71), 0.67 (95% CI, 0.52-0.83), and 0.59 (95% CI, 0.43-0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49-0.99), 0.76 (95% CI, 0.46-0.99), and 0.89 (95% CI, 0.67-0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66-0.85) for reader 1, 70 of 88 (0.80; 0.70-0.87) for reader 2, and 73 of 96 (0.76; 0.66-0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for 68Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility.
引用
- Kuo PH, Yoo DC, Avery R, et al. A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2023. PMID: 37230533. doi:10.2967/jnumed.122.265077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。